Qarziba (Dinutuximab Beta)

Qarziba (dinutuximab beta) is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed or refractory neuroblastoma, with or without residual disease. Before the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilized by other suitable measures.

In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first-line therapy, dinutuximab beta should be combined with interleukin-2 (IL-2).

Recommended Dosage:
Qarziba has a restriction to hospital use only, and it must be administered by a qualified physician experienced in administering oncological therapies. The healthcare professional must be capable of treating life-threatening allergic reactions such as anaphylaxis, and must be situated in a location where complete resuscitation can be provided immediately.

Treatment with Qarziba comprises five consecutive courses, each lasting 35 days. The treatment is dosed at 100 mg/m2 per course, which is further divided over the 35 days, and calculated based on body surface area.

Two modes of administration are possible:

• a continuous infusion over the first 10 days of each course (a total of 240 hours) at the daily dose of 10 mg/m2
• or five daily infusions of 20 mg/m2 administered over 8 hours, on the first 5 days of each course.

When IL-2 is combined with Qarziba, it should be administered as subcutaneous injections of 6×106 IU/m2 /day, for 2 periods of 5 consecutive days, resulting in an overall dose of 60×106 IU/m2 per course. The first 5-day course should start 7 days before the first infusion of dinutuximab beta, and the second 5-day course should start concurrently with dinutuximab beta infusion (days 1 to 5 of each dinutuximab beta course).

• Dinutuximab beta can cause ocular issues like blurred vision, photophobia, mydriasis, and accommodative anomalies. Regular eye check-ups should be conducted during treatment, and any visual changes should be communicated immediately.
• Neurological complications, including urinary retention and transverse myelitis, may occur. Monitor for signs and symptoms of spinal cord involvement, such as motor weakness, back pain, or bladder/bowel dysfunction. Stop therapy if transverse myelitis is suspected.
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS) is a rare but serious complication associated with dinutuximab beta. Symptoms such as headaches, changes in vision, seizures, and sometimes altered mental status can occur. An MRI can confirm the diagnosis. Treatment should be stopped in patients suspected of having RPLS, and they should be managed appropriately.
• Patients may experience capillary leak syndrome with hypotension, edema, hypoalbuminemia, and hemoconcentration. Precise monitoring of fluid balance and blood pressure is critical. If life-threatening hypotension occurs, treatment should be suspended.
• Those receiving dinutuximab beta may face immune suppression and heightened risk of bacterial, viral, and fungal infections. Infection signs should be watched for, and action taken without delay. Preventative measures should be considered in high-risk patients.
• During therapy, neutropenia, thrombocytopenia, and anemia may occur. Regular complete blood counts are vital. In patients suffering from severe myelosuppression, treatment should not be initiated until recovery is achieved.
• Dinutuximab beta may cause hypokalemia, hyponatremia, hypocalcemia, and hypophosphatemia. Ensure serum electrolytes are monitored and any abnormalities corrected before or during treatment.
• Atypical Hemolytic Uremic Syndrome (aHUS) is a rare but potentially life-threatening complications characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury.
• Discontinue treatment promptly in case signs of aHUS occur, and manage with appropriate supportive care.
  Dinutuximab beta may cause fetal damage if given to a pregnant woman. Women of childbearing potential should be counseled on the necessitous of using effective contraception during treatment and for at least six months post therapy. Do not use during pregnancy unless absolutely necessary.

What documents are required to import QARZIBA to India?

QARZIBA (dinutuximab beta) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is QARZIBA available in India?

QARZIBA (dinutuximab beta injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Qarziba in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

QARZIBA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of QARZIBA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Qarziba 4.5 mg/mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source QARZIBA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Qarziba®?

Dinutuximab Beta is the Generic Name for the trade name drug Qarziba®.

What is the Manufacturer's Name of Qarziba®?

Qarziba® is manufactured by EUSA Pharma Ltd.

What is the dosage and form of Qarziba® supplied?

Qarziba is supplied in an injection: 4.5 mg/mL for intravenous (IV) infusion.

What are the most common side effects of Qarziba® 4.5 mg/mL injection?

The most common side effects of Qarziba® are pain, urticaria, pyrexia, lymphopenia, thrombocytopenia, infusion reactions, vomiting, hypotension, increased alanine aminotransferase, anemia, capillary leak syndrome, diarrhea, hypokalemia, hyponatremia, neutropenia, hypoalbuminemia, hypocalcemia, and increased aspartate aminotransferase.

How much does Qarziba® 4.5 mg/mL injection cost in India?

Qarziba® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Prices of Qarziba injection may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Qarziba 4.5 mg/mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Qarziba® 4.5 mg/mL injections be available in SAARC countries?

Apart from Gulf countries, Qarziba® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Qarziba® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Qarziba® 4.5 mg/mL injection online in India?

Yes, one can buy Qarziba 4.5 mg/mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Qarziba® injection through legal channels.

What are the storage conditions of Qarziba® 4.5 mg/mL injections?

Store in a refrigerator (2 °C to 8 °C). Keep the vial in the outer carton to protect it from light. Once opened, this therapeutic drug is intended for immediate use.